BiomX Inc.
PHGE evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for PHGE—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PHGE
BiomX Inc. is a clinical-stage biotechnology company developing phage-based therapies for chronic bacterial infections, currently undergoing a strategic transformation after discontinuing its lead candidate and facing a going concern uncertainty.
Key risk: Going concern uncertainty
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 3 clinical trials for BiomX Inc..
BiomX Inc. is a clinical-stage biotechnology company developing phage-based therapies for chronic bacterial infections, currently undergoing a strategic transformation after discontinuing its lead candidate and facing a going concern uncertainty.
- BiomX is a clinical-stage company developing phage-based therapies targeting bacterial pathogens implicated in chronic diseases [sec · filed 2026-06-29].
- As of 2026-06-30, the company reported cash & equivalents of $0.3M, total revenue of $0.3M, net income of -$3.8M, shareholders' equity of $19.2M, and total debt of $0.5M [sec].
- In December 2025, the company discontinued development of BX004, its lead phage product candidate, and its former Israeli subsidiary commenced insolvency proceedings [sec · filed 2026-06-29].
- The company has incurred significant operating losses and has not generated any revenue from product sales [sec_mda · as of 2026-02-19].
- Management has expressed substantial doubt about the company's ability to continue as a going concern, with cash expected to fund operations only through the end of the second quarter of 2026 [sec_mda · as of 2026-02-19].
What works
- The company has a diversified pipeline of phage-based therapies targeting chronic bacterial infections, including diabetic foot osteomyelitis (DFO) and diabetic foot infections (DFI) [sec_mda · as of 2026-02-19].
- An independent Data Monitoring Committee recommended continuation of a study with an adjusted dosing regimen, suggesting ongoing clinical development [sec · filed 2025-11-25].
- The company has received gross proceeds of approximately $217.3 million from sales of securities and $14.7 million from collaboration agreements and grants as of December 31, 2025 [sec_mda · as of 2026-02-19].
What to weigh
- The company has no approved products and has not generated any revenue from product sales [sec_mda · as of 2026-02-19].
- As of 2026-06-30, cash & equivalents were only $0.3M, and the company faces a going concern uncertainty with cash expected to last only through the end of the second quarter of 2026 [sec_mda · as of 2026-02-19] [sec].
- The company discontinued its lead product candidate BX004 and its Israeli subsidiary commenced insolvency proceedings, reflecting significant operational setbacks [sec · filed 2026-06-29].
- The company is pursuing strategic alternatives, indicating uncertainty about its future direction and ability to continue operations [sec_mda · as of 2026-02-19].
From the filings
Quoted directly from source documents.
The company discontinued its lead product candidate BX004 and its Israeli subsidiary commenced insolvency proceedings.
“In December 2025, the Company discontinued the development of BX004, its lead phage product candidate, and its former Israeli operating subsidiary, BiomX Ltd., commenced insolvency proceedings in Israel.”
SEC filings · June 29, 2026
The company has not generated any revenue from product sales.
“We do not have any products approved for sale, and we have not generated any revenue from product sales.”
SEC MD&A · February 19, 2026
Management has expressed substantial doubt about the company's ability to continue as a going concern.
“Our financial statements contain an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern, as we believe our cash and cash equivalents on hand will be sufficient to meet our working capital and capital expenditure requirements only through the end of the second quarter of 2026”
SEC MD&A · February 19, 2026
The company is pursuing strategic alternatives.
“In addition to continuing our current business, we are pursuing strategic alternatives.”
SEC MD&A · February 19, 2026
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — Cash of $0.3M as of 2026-06-30 may only fund operations through Q2 2026 [sec] [sec_mda · as of 2026-02-19].
- No approved products or revenue — The company has no products approved for sale and has not generated any product revenue [sec_mda · as of 2026-02-19].
- Lead candidate discontinued — BX004 development was discontinued in December 2025, and the Israeli subsidiary entered insolvency [sec · filed 2026-06-29].
- Clinical development risks — Results of preclinical studies and early trials may not be replicated in later trials [sec · filed 2025-12-11].
What to watch
- Topline results from the ongoing study with adjusted dosing regimen, expected in the second quarter of 2026, pending financial resources [sec · filed 2025-11-25].
- Outcome of the company's pursuit of strategic alternatives, which could include a sale, merger, or other transaction [sec_mda · as of 2026-02-19].
- Ability to secure additional financing to extend cash runway beyond the end of the second quarter of 2026 [sec_mda · as of 2026-02-19].
- Progress in developing product candidates for diabetic foot osteomyelitis (DFO) and diabetic foot infections (DFI) [sec_mda · as of 2026-02-19].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run BiomX Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available BiomX Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
2.9 months
D/E 0.97 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
0 buys · 4 sells (180d)
Runway
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
9
Total value held
$616K
| Holder | Shares | Value |
|---|---|---|
| deerfield management company, l.p. | 131,272 | $493K |
| morgan stanley | 19,100 | $72K |
| jane street group, llc | 11,829 | $44K |
| barclays plc | 1,316 | $5K |
| royal bank of canada | 251 | $1K |
| osaic holdings, inc. | 200 | $750 |
| sbi securities co., ltd. | 20 | $75 |
| cwm, llc | 1 | $4 |
| danske bank a/s | 1 | $4 |
Short Interest
as of May 22, 2026- % of float
- 1.0%
- Days to cover
- 0.2
- Shares short
- 91,280
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PHGE short interestGovernance
Frequently asked questions
What is the AI investment thesis for BiomX Inc.?
BiomX Inc. is a clinical-stage biotechnology company developing phage-based therapies for chronic bacterial infections, currently undergoing a strategic transformation after discontinuing its lead candidate and facing a going concern uncertainty.
Who is the CEO of BiomX Inc.?
Mr. Michael Oster is the chief executive officer of BiomX Inc. (PHGE).
Where is BiomX Inc. headquartered?
BiomX Inc. (PHGE) is headquartered in Dover, DE, United States.
What therapeutic areas does BiomX Inc. focus on?
BiomX Inc. develops therapies across Oncology, Rare Disease, Immunology, Respiratory, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.